Pipeline

Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs

COVI-TRACE™ Diagnostic Test

0%*

FDA Emergency Use Authorization (EUA) Application Expected

COVI-TRACK™ Antibody Test

0%*

FDA Emergency Use Authorization (EUA) Application Under Review

COVI-GUARD™ Neutralizing Antibody

30%*

COVI-AMG™ Neutralizing Antibody

10%*

COVI-SHIELD™ Antibody Cocktail

10%*

COVIDTRAP™ ACE2 Receptor Decoy

10%*

T-VIVA-19™ Vaccine

10%*

ABIVERTINIB Cytokine Storm

55%*

Immunotherapy

 

CD38 CAR-T Multiple Myeloma

30%*

CD38 DAR-T Multiple Myeloma

10%*

CD38 ADC Amyloidosis

30%*

Seprehvir™ Solid Tumors

30%*

ABIVERTINIB NSCLC

80%*

ADNIC Solid and Liquid Tumors

55%*

Pain

RTX (resiniferatoxin)
Epidural route
Terminal Cancer Pain

55%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe OA

55%*

RTX (resiniferatoxin)
Intra-articular route
TKR Deferment

55%*

Lymphatic Delivery

Sofusa® anti-TNF Autoimmune

30%*

Sofusa® anti-PD-1 CTCL

30%*

COVID-19 Programs
Key Programs (Indication) Phase
COVI-TRACE™ (Diagnostic Test) FDA EUA
COVI-TRACK™ (Antibody Test) FDA EUA
COVI-GUARD™ Ph I
COVI-AMG™ Preclinical
COVI-SHIELD™ Preclinical
COVIDTRAP™ Preclinical
T-VIVA-19™ (Vaccine) Preclinical
ABIVERTINIB (Cytokine Storm) Ph II
Immunotherapy
Key Programs (Indication) Phase
CD38 CAR-T (Multiple Myeloma) Ph I
CD38 DAR-T (Multiple Myeloma) Preclinical
CD38 ADC (Amyloidosis) Ph I
Seprehvir™ (Solid Tumors) Ph I
ABIVERTINIB (NSCLC) PhIII/Pivotal
ADNIC (Solid and Liquid Tumors) Ph II
Pain
Key Programs (Indication) Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II
RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II
RTX (resiniferatoxin) Intra-articular route (TKR Deferment) Ph II
Lymphatic Delivery
Key Programs (Indication) Phase
Sofusa® anti-TNF (Autoimmune) Ph I
Sofusa® anti-PD-1 (Immuno Oncology) Ph I